Astellas Announces Positive Findings from Phase 3 GLOW Trial of Zolbetuximab during March ASCO Plenary Series

/PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") will present detailed results from the Phase 3 GLOW...

Related Keywords

Australia ,Guangzhou ,Guangdong ,China ,New York ,United States ,Shitara ,Aichi ,Japan ,Tokyo ,United Kingdom ,Canada ,Northbrook ,Queensland ,America ,American ,Kenji Yasukawa ,Ahsan Arozullah ,Rui Hua Xu ,Manisha Shah ,National Cancer Institute ,American Society Of Clinical Oncology ,Sun Yat Sen University Cancer Center ,Department Of Medical Oncology ,End Results Program ,Astellas Pharma Inc ,Head Of Development Therapeutic Areas ,Gastrointestinal Oncology Program ,Prnewswire Astellas Pharma Inc ,American Cancer Society ,Medical Oncology ,March American Society ,Clinical Oncology ,Plenary Series ,Medical Oncologist ,Weill Cornell Medicine ,Senior Vice President ,Development Therapeutic Areas ,Locally Advanced Unresectable Metastatic Gastric ,Gastroesophageal Junction ,South America ,Primary Focus ,Focus Area Approach ,Astellas Pharma ,End Results ,